Title:
Author: Messina, Nicole L.; Pittet, Laure F.; McDonald, Ellie; Moore, Cecilia; Barry, Simone; Bonten, Marc; Byrne, Anthony; Campbell, John; Croda, Julio; Croda, Mariana G.; Dalcolmo, Margareth; de Almeida E Val, Fernando F.; de Oliveira, Roberto D.; Dos Santos, Glauce; Douglas, Mark W.; Gardiner, Kaya; Gwee, Amanda; Jardim, Bruno A.; Kollmann, Tobias; Lacerda, Marcus; Lucas, Michaela; Lynn, David J.; Manning, Laurens; Marshall, Helen; O’Connell, Abby; Perrett, Kirsten P.; Post, Jeffrey J.; Prat-Aymerich, Cristina; Rocha, Jorge L.; Rodríguez-Baño, Jesus CSIC ORCID; Wadia, Ushma; Warris, Adilia; Davidson, Andrew; Curtis, Nigel
Funders: Bill & Melinda Gates Foundation
Minderoo Foundation
Royal Children’s Hospital Foundation
Health Services Union New South Wales Branch
Peter Sowerby Foundation
Insurance Advisernet Foundation
NAB Foundation
Calvert-Jones Foundation
Modara Pines Charitable Foundation
Victoria State Government
National Health and Medical Research Council (Australia)
Swiss National Science Foundation
Medical Research Council (UK)
Keywords: Bacillus Calmette-Guérin (BCG) Vaccine
Breakthrough infection
COVID-19
Immunity
Randomised controlled trial
Publication date: oct-2024
Editor: Elsevier
Citation: Journal of Infection 89(4): 106245 (2024)
Summary: Bacille Calmette-Guérin (BCG) vaccine has immunomodulatory effects that may provide protection against unrelated infectious diseases. We aimed to determine whether BCG vaccination protects adults against COVID-19.
Publisher version:
URI:
DOI: 10.1016/j.jinf.2024.106245
ISSN: 0163-4453
E-ISSN: 1532-2742
License to use:
Source works: The underlying dataset has been published as supplementary material of the article in the publisher platform at
(IBIS) Articles
